跳至主要内容
临床试验/ACTRN12609000108213
ACTRN12609000108213尚未招募2 期

The utility of 18F-fluro-deoxy-glucose (FDG) and 11C-choline (C) positron emission tomography (PET) scan in men with localised prostate cancer planned for radiotheraupetic management

Austin Health0 个研究点目标入组 30 人开始时间: 2009年2月16日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
Austin Health
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Male

入选标准

  • PSA > 20 or Gleason score 8-10 or T stage T3a,T3b or T4
  • Age > 18 years
  • Eastern Cooperative Oncology Group Performance Status (ECOG) 0 or 1
  • No significant medical or psychiatric illness
  • Written informed consent
  • Be prepared to undergo PET scanning

排除标准

  • Any form of prostate malignancy
  • T1-2c prostate cancer and PSA , 10 and Gleason score < 7
  • Previous radical prostatectomy
  • Known metastatic prostate cancer
  • Contraindication to MRI
  • Contraindication to androgen ablation
  • Contraindication to PET
  • Commencement of androgen depriavation therapy prior to study entry
  • Previous pelvic radiotherapy
  • Contraindication to radiotherapy

研究者

发起方
Austin Health

相似试验